{"id":"tramiprosate-3aps","safety":{"commonSideEffects":[{"rate":null,"effect":"Meningoencephalitis"},{"rate":null,"effect":"Amyloid-related imaging abnormalities (ARIA)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Tramiprosate (3APS) is a small molecule that binds to soluble amyloid-beta peptides and prevents their polymerization into toxic aggregates. By stabilizing monomeric amyloid-beta and promoting its clearance from the central nervous system, it aims to slow cognitive decline in Alzheimer's disease. The drug targets the pathological hallmark of Alzheimer's disease—amyloid plaque accumulation—rather than downstream inflammatory or tau-related pathways.","oneSentence":"Tramiprosate inhibits amyloid-beta aggregation and promotes its clearance, reducing amyloid plaque formation in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:45.345Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild cognitive impairment due to Alzheimer's disease"},{"name":"Mild dementia due to Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT00314912","phase":"PHASE3","title":"Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease","status":"UNKNOWN","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2006-05","conditions":"Alzheimer's Disease","enrollment":650}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tramiprosate (3APS)","genericName":"Tramiprosate (3APS)","companyName":"Bellus Health Inc. - a GSK company","companyId":"bellus-health-inc-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tramiprosate (3APS) is a small molecule that stabilizes amyloid-beta A4 protein. It has been studied in clinical trials for the treatment of Alzheimer's Disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}